QR Code

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	M Rizzo, I Colomer-Asenjo, G Cabello-Molina, S Marín-López, M Sutil-Vega, C Roca-Guerrero, F Taibi-Hajjami, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Format:	article
Langue:	EN
Publié:	Radcliffe Medical Media 2020
Sujets:	Diseases of the circulatory (Cardiovascular) system RC666-701
Accès en ligne:	https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
par: M Rizzo, et autres
Publié: (2020)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
par: Osama A. Amin, et autres
Publié: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
par: Mauro Gori, et autres
Publié: (2021)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
par: Maria Vincenza Polito, et autres
Publié: (2020)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
par: Domingo Pascual-Figal, et autres
Publié: (2021)

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
par: Pankaj Jariwala, et autres
Publié: (2021)

Sacubitril/valsartan in real-life clinical practice
par: Yüksel Çavuşoğlu
Publié: (2021)

Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
par: Jiao Ai, et autres
Publié: (2021)

Renal protective effect of sacubitril/valsartan in patients with heart failure
par: Hui-Ling Hsieh, et autres
Publié: (2021)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
par: Cuthbert JJ, et autres
Publié: (2020)

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts
par: Xiaofei Li, et autres
Publié: (2021)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
par: Oriol Iborra-Egea, et autres
Publié: (2017)

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
par: Hyoeun Kim, et autres
Publié: (2021)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
par: Elodie Charuel, et autres
Publié: (2021)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
par: Tara Snyder, et autres
Publié: (2019)

Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
par: Ferhat Dindaş, et autres
Publié: (2021)

Classification of heart failure: A farewell to ejection fraction?
par: Thomas F. Lüscher
Publié: (2021)

Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction
par: Nancy Luo, MD, MHS, et autres
Publié: (2021)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
par: Veronika Zach, et autres
Publié: (2020)

Role of nutritional supplementation in heart failure with reduced ejection fraction
par: Yash Paul Sharma, et autres
Publié: (2021)

Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional
par: Prat M.,Hernán
Publié: (2000)

Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy
par: Maria Calderon-Dominguez, et autres
Publié: (2021)

Visual versus fully automated assessment of left ventricular ejection fraction
par: Rami Mahmood Abazid, et autres
Publié: (2018)

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction
par: Ali Çoner, et autres
Publié: (2021)

Determinants of gait speed in patients with heart failure with reduced ejection fraction
par: Aylin Tanrıverdi, et autres
Publié: (2021)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
par: M. A. Manukyan, et autres
Publié: (2021)

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
par: Neal M Dixit, et autres
Publié: (2021)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
par: Hidekatsu Fukuta
Publié: (2020)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
par: Davide Margonato, et autres
Publié: (2020)

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.
par: Jae Hyung Cho, et autres
Publié: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
par: Li-fang Ye, et autres
Publié: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
par: Gaurav Aggarwal, et autres
Publié: (2021)

Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype
par: Rebecca T. Levinson, et autres
Publié: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
par: Sebastian Rosch, et autres
Publié: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
par: Sebastiaan HC Klaassen, et autres
Publié: (2020)

Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
par: Pankaj Garg, et autres
Publié: (2021)

Non-Invasive Assessment of Left Ventricle Ejection Fraction: Where Do We Stand?
par: Alessandra Scatteia, et autres
Publié: (2021)

Magnetic Resonance Assessment of Ejection Fraction Versus Echocardiography for Cardioverter-Defibrillator Implantation Eligibility
par: Călin Schiau, et autres
Publié: (2021)

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
par: Feng Liu, et autres
Publié: (2014)

Chamber-enriched gene expression profiles in failing human hearts with reduced ejection fraction
par: Xin Luo, et autres
Publié: (2021)